CTU: A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor Directed Therapy in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Chemotherapy

  • Gurney, Howard (Primary Chief Investigator)
  • Martin, Lewis (Clinical Trial Unit Staff)
  • Garcia, Michelle (Clinical Trial Unit Staff)
  • Quinlan, Gabriel (Clinical Trial Unit Staff)
  • TAIDI, Gina (Clinical Trial Unit Staff)
  • Chapman, Nicola (Clinical Trial Unit Staff)
  • Armstrong, Emilia (Clinical Trial Unit Staff)

Project: Research

Project Details

Short title20230005
StatusActive
Effective start/end date6/02/25 → 27/11/29